Sarepta Therapeutics Inc. (SRPT) had a rough trading day for Monday October 07 as shares tumbled 8.26%, or a loss of $-7.29 per share, to close at $80.96. After opening the day at $87.90, shares of Sarepta Therapeutics Inc. traded as high as $88.98 and as low as $80.50. Volume was 2.85 million shares over 30,972 trades, against an average daily volume of n/a shares and a total float of 74.34 million.
As a result of the decline, Sarepta Therapeutics Inc. now has a market cap of $6.02 billion. In the last year, shares of Sarepta Therapeutics Inc. have traded between a range of $158.80 and $72.05, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta’s strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta’s product candidates are at an early stage of development.
Sarepta Therapeutics Inc. is based out of Cambridge, MA and has some 499 employees. Its CEO is Douglas S. Ingram.
Sarepta Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
